Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study.

Among patients who reported abdominal pain, the proportion who reported any level of interference with usual/daily activities showed a decreasing trend over the course of treatment compared with baseline values (durvalumab plus EP, 75% at baseline to 45% in cycle 7; EP, 73% at baseline to 50% in cycle 7; data for cycle 8 are not reported as there were ≤5 respondents in each arm) ( Figure 4(b) ).

also in 47,180 other papers